NORTH HOLLYWOOD, Calif. & WURZBURG, Germany--(BUSINESS WIRE)--The International Myeloma Foundation (IMF) – supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians – today said the positive opinion from the European Medicines Agency (EMEA) could clear the way for a new treatment regimen in Europe. The decision recommends approval of Thalidomide Pharmion® in combination with melphalan and prednisone for newly diagnosed patients over 65.
